4BIO Capital - 4BIO invests in Araris Biotech AG’s CHF 15.2 million seed financing round

4BIO Capital announces its investment in Araris Biotech AG, a company pioneering an antibody-drug conjugate (ADC)-linker technology. Araris announced today that it has received an additional CHF 12.7 million in its seed financing round, bringing the total amount raised to CHF 15.2 million. Dmitry Kuzmin, Managing Partner at 4BIO Capital, will join Araris’ Board.